CytomX Therapeutics Announces Details of Presentations at the American Society of Clinical Oncology ASCO20 Virtual Scientific Program

South San Francisco, CA - May 13, 2020 - CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® therapeutic technology platform, today announced further details of oral and poster presentations at the American Society of Clinical Oncology’s (ASCO) ASCO20 Virtual Scientific Program taking place from May 29 - May 31, 2020.

Presentation titles, presenters and timing are listed below with all abstracts available at the ASCO20 Meeting Library.

CytomX’s ASCO20 clinical presentations for CX-072 (Abstract 3005), CX-2009 (Abstract 526) as well as CX-2029 (Abstract 3502), developed in partnership with AbbVie, will have data cutoff dates of approximately five months later than the abstract data cutoff. All presentations will be available on Friday, May 29, 2020, 8:00 am EDT.

“Our upcoming presentations at ASCO highlight the broad progress that has been made across our clinical stage portfolio and the potential of our Probody platform,” said Alison L. Hannah, M.D., chief medical officer of CytomX Therapeutics. “We look forward to sharing this comprehensive update that includes the first clinical data for CX-2029, a first in class Probody Drug Conjugate targeting CD71, as well as new data to support CX-2009 moving into later stage trials in breast cancer. These and other programs in our pipeline, including CX-072, a Probody checkpoint inhibitor and BMS-986249, the anti-CTLA-4 Probody therapeutic being developed in collaboration with Bristol Myers Squibb have the potential to deliver meaningful advances for patients with cancer.”

Abstract 3502

CX-2029, a PROBODY Drug Conjugate Targeting CD71 (Transferrin Receptor): Results from a First-in-Human Study (PROCLAIM-CX-2029) in Patients (Pts) With Advanced Cancer

Presenter: Melissa L. Johnson, M.D., Sarah Cannon Research Institute at Tennessee Oncology, Nashville

Session Title: Developmental Therapeutics—Immunotherapy

Session Date and Time: Friday, May 29, 2020 8:00 am EDT

Session Type: Oral Presentation

Abstract 526 Poster 18

CX-2009, A CD166-Directed PROBODY Drug Conjugate (PDC): Results From the First-in-Human Study in Patients With Advanced Cancer Including Breast Cancer

Presenter: Valentina Boni, M.D., Ph. D., START Madrid – CIOCC, Madrid, Spain

Session Title: Developmental Therapeutics—Immunotherapy

Session Date and Time: Friday, May 29, 2020 8:00 am EDT

Session Type: Poster Presentation

Abstract 3599 Poster 329

Preliminary Clinical Pharmacokinetics and Dose-Response to Support a Phase 2 Dose Selection for CX-
2009: A Masked PROBODY Drug Conjugate to CD166

**Presenter:** Mark Stroh, Ph.D., CytomX Therapeutics

**Session Title:** Developmental Therapeutics—Immunotherapy

**Session Date and Time:** Friday, May 29, 2020 8:00 am EDT

**Session Type:** Poster Presentation

**Abstract**

**PROCLAIM-CX-072: Analysis of Patients With Advanced Solid Tumors Receiving Long-Term Treatment With CX-072, a PD-L1 PROBODY Therapeutic, as a Single Agent or in Combination With Ipilimumab**

**Presenter:** Fiona C. Thistlethwaite, MB, MChir, Ph.D, The Christie NHS Foundation Trust, University of Manchester, United Kingdom

**Session Title:** Developmental Therapeutics—Immunotherapy

**Session Date and Time:** Friday, May 29, 2020 8:00 am EDT

**Session Type:** Oral Presentation

**Abstract**

**Evidence of Intratumoral Localization, Activation, and Immunomodulatory Effect of CX-072, a PROBODY Therapeutic Targeting PD-L1, in a Phase 1/2 Trial**

**Presenter:** Susan K. Lyman, CytomX Therapeutics

**Session Title:** Developmental Therapeutics—Immunotherapy

**Session Date and Time:** Friday, May 29, 2020 8:00 am EDT

**Session Type:** Poster Presentation

**Abstract**

**Preliminary Population Pharmacokinetics Supports Phase 2 Dose Selection for Masked Anti–PD-L1 Antibody CX-072**

**Presenter:** Mark Stroh, Ph.D., CytomX Therapeutics

**Session Title:** Developmental Therapeutics—Immunotherapy

**Session Date and Time:** Friday, May 29, 2020 8:00 am EDT

**Session Type:** Poster Presentation

**Abstract**

**Anti–CTLA-4 probody BMS-986249 Alone or in Combination with Nivolumab in Patients with Advanced Cancers: Initial Phase 1 Results**

**Presenter:** Martin Gutierrez, M.D. Hackensack University Medical Center, Hackensack, New Jersey

**Session Title:** Developmental Therapeutics—Immunotherapy

**Session Date and Time:** Friday, May 29, 2020 8:00 am EDT

**Session Type:** Poster Presentation

**About CytomX Therapeutics**

CytomX is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies. We are developing a novel class of investigational antibody therapeutics, based on our Probody® technology platform, for the treatment of cancer.

Probody therapeutics are designed to remain inactive until they are activated by proteases in the tumor microenvironment. As a result, Probody therapeutics are intended to bind selectively to tumors and
decrease binding to healthy tissue, to minimize toxicity and potentially create safer, more effective therapies. As leaders in the field, our innovative technology is designed to turn previously undruggable targets into druggable targets and to enable more effective combination therapies. CytomX and its partners, comprised of leading biotechnology and pharmaceutical companies, have developed a robust pipeline of potential first-in-class therapeutic candidates against novel, difficult to drug targets and potential best-in-class immunotherapeutic candidates against clinically validated targets. The CytomX clinical stage pipeline includes first-in-class product candidates against previously undruggable targets, including a CD166-targeting Probody drug conjugate wholly owned by CytomX (CX-2009) and a CD71-targeting Probody drug conjugate partnered with AbbVie (CX-2029). CD166 and CD71 are among cancer targets that are considered to be inaccessible to conventional antibody drug conjugates due to their presence on many healthy tissues. The CytomX clinical stage pipeline also includes cancer immunotherapeutic candidates against validated targets such as the CTLA-4-targeting Probody therapeutics, BMS-986249 and BMS-986288, partnered with Bristol Myers Squibb. CytomX has strategic drug discovery and development collaborations with AbbVie, Amgen, Astellas and Bristol Myers Squibb. For additional information about CytomX Therapeutics, visit www.cytomx.com and follow us on LinkedIn and Twitter.

CytomX Therapeutics Forward-Looking Statements

This press release includes forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that are difficult to predict, may be beyond our control, and may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied in such statements. Accordingly, you should not rely on any of these forward-looking statements, including those relating to the potential benefits, safety and efficacy or progress of CytomX’s or any of its collaborative partners’ product candidates, the potential benefits or applications of CytomX’s Probody platform technology, and CytomX’s ability to develop and advance product candidates into and successfully complete clinical trials, including the ongoing and planned clinical trials of CX-2009 and CX-2029. Risks and uncertainties that contribute to the uncertain nature of the forward-looking statements include: the unproven nature of CytomX’s novel Probody Platform technology; CytomX’s clinical trial product candidates are in the initial stages of clinical development and its other product candidates are currently in preclinical development, and the process by which preclinical and clinical development could potentially lead to an approved product is long and subject to significant risks and uncertainties, including the risk that the COVID-19 worldwide pandemic may continue to negatively impact the business, research and clinical operations of CytomX or its partners, including the development of preclinical drug candidates due to delays in and disruption of research activities and the development of clinical drug candidates due to delays in or disruption of clinical trials, including impacts on the enrollment of patients in clinical trials or other clinical trial disruptions; the possibility that the results of early clinical trials may not be predictive of future results; the possibility that CytomX’s clinical trials will not be successful; the possibility that current preclinical research may not result in additional product candidates; CytomX’s dependence on the success of CX-2009, CX-2029, BMS-986249 and BMS-986288; CytomX’s reliance on third parties for the manufacture of the company’s product candidates; and possible regulatory developments in the United States and foreign countries. Additional applicable risks and uncertainties include those relating to our preclinical research and development, clinical development, and other risks identified under the heading "Risk Factors" included in CytomX’s Quarterly Report on Form 10-Q filed with the SEC on May 7, 2020. The forward-looking statements contained in this press release are based on information currently available to CytomX and speak only as of the date on which they are made. CytomX does not undertake and
specifically disclaims any obligation to update any forward-looking statements, whether as a result of any new information, future events, changed circumstances or otherwise.

Probody is a U.S. registered trademark of CytomX Therapeutics, Inc.

Investor and Media Contact:

Christopher Keenan  
VP, Investor Relations and Corporate Communications  
ckeenan@cytomx.com  
650-383-0823